Evidence-based articles on weight loss, GLP-1 medications, nutrition, and metabolic health — organized by topic. Written and reviewed by independent licensed providers.
A Formulation Problem That Reached the Emergency Department A patient presents with an injection-site abscess three weeks into a subcutaneous semaglutide protocol sourced from a state-licensed…
Trial readouts, endpoints, and what the data does — and does not — establish.
What the 48-week Phase 2 data on retatrutide reported for weight and glycemic endpoints, with every figure attributed to the published trial. Retatrutide is investigational and not FDA-approved.
When Weight Loss Becomes a Sleep Apnea Treatment Picture a 54-year-old patient — moderately obese, CPAP-dependent for six years, compliance at maybe 60% on a good month. He shows up to a weight…
A Problem That Weight Loss Alone Wasn't Solving Picture a 54-year-old male patient — 118 kg, BMI 38, moderate-to-severe obstructive sleep apnea confirmed by polysomnography. He's been on CPAP for…
Why the Retatrutide Phase 3 Readout Is the Most-Watched Trial in Metabolic Medicine Right Now Imagine running a weight management clinic. Your best patients on semaglutide 2.4 mg hit a wall at…
Head-to-head pharmacology: efficacy, dosing, tolerability, and approval status.
A patient presents with a BMI of 38, newly diagnosed hypertension, and no personal or family history of medullary thyroid carcinoma. The clinical question — tirzepatide or semaglutide — previously…
Two Drugs, One Question: Which Actually Moves the Needle? A patient walks into a weight management clinic having already tried liraglutide (Victoza/Saxenda) for 52 weeks. They lost 6% of their body…
Tirzepatide reset the weight-loss benchmark in 2022. Three years later the comparative-effectiveness data has caught up, and the answer to "is tirzepatide better than semaglutide for obesity?" is…
Semaglutide vs tirzepatide vs retatrutide: a data-driven comparison of efficacy, side effects, and clinical-trial results, with each agent's regulatory status noted.
Receptor biology and pharmacokinetics behind the incretin class.
In 2018, the SELECT investigators enrolled the first of what would become 17,604 participants — none diabetic, all obese or overweight, every one carrying a history of established cardiovascular…
A 54-year-old woman with a BMI of 38 kg/m² and hypertension has cycled through two GLP-1 receptor agonists over four years, reaching a maximum of 11% body weight reduction before plateauing on…
Why Nausea on a GLP-1 Drug Is Not Random — It Is Pharmacologically Predictable A patient initiates semaglutide (Ozempic) at 0.25 mg/week. By day ten, meals trigger nausea intense enough to alter…
A patient arrives at an obesity medicine consultation after 24 weeks on semaglutide (Wegovy) 2.4 mg weekly with a 6.2% body weight reduction — statistically real, clinically insufficient for a…
A patient initiates semaglutide (Ozempic) at 0.25 mg/week and reports nausea beginning on day 3 of the first injection. By week 4 at the same dose, the nausea has largely resolved. By week 12…
How retatrutide's triple-receptor mechanism (GIP, GLP-1, and glucagon) is studied for weight regulation, with trial-reported figures attributed to published sources. Investigational; not FDA-approved.
Compound-level profiles across the research-peptide landscape.
A weight management clinic enrolling 40 consecutive patients on semaglutide 2.4 mg (Wegovy) in 2022 saw outcomes closely tracking the 14.9% mean body weight reduction reported in STEP 1 — a…
The Problem Nobody Talks About When Patients Start GLP-1 Therapy A 52-year-old male patient starts semaglutide at 0.25 mg/week. By week 12, he's down 18 pounds — but he's also reporting a nagging…
Reconstitution, storage, and handling for laboratory research.
Reconstitution diluent selection is one of the more consequential — and most under-documented — decisions in peptide research. The two diluents in widest use, bacteriostatic water for injection…
Adverse-event data, contraindications, and tolerability signals.
A Formulation Problem That Reached the Emergency Department A patient presents with an injection-site abscess three weeks into a subcutaneous semaglutide protocol sourced from a state-licensed…
The scenario presents itself with increasing frequency in obesity medicine practice: a patient who has completed 36 weeks of tirzepatide (Mounjaro/Zepbound) titration, achieved 10 mg or 15 mg/week…
A patient presents with severe obstructive sleep apnea — apnea-hypopnea index (AHI) of 64 events per hour — and a BMI of 39 kg/m². Two CPAP trials have failed: one due to claustrophobia, one due to…
GLP-1 therapy and lean muscle mass preservation represent one of the most clinically consequential body composition questions in pharmacological weight management. A patient on semaglutide 2.4 mg…
A patient with a BMI of 38 initiates semaglutide 0.25 mg/week (Wegovy) and advances on calendar schedule at week 4 to 0.5 mg. Nausea begins on day 2 of the new dose. At week 8, the prescriber…
The Patient Who Stopped Too Soon A 47-year-old woman, 214 lbs at peak, had worked down to 171 lbs over 14 months on semaglutide 2.4 mg weekly. She felt great. Her physician agreed she could take a…
Regulatory status, shortages, compounding, and the access landscape.
The Shortage Is Over — But the Access Problem Isn't In February 2025, the FDA officially removed semaglutide from its drug shortage database. On paper, that sounds like a win. In practice…
Plain-language starting points for the GLP-1 / GLP-3 landscape.
Clinical evidence and mechanism of action for GLP-1 and GLP-3 weight-loss therapies, sourced from peer-reviewed trials and medical literature.
An introduction to GLP3 Weight Loss as an independent educational resource and research-product catalog — what we are, what we are not, and how we connect readers with independent licensed providers.
A practical, evidence-based primer on GLP-1 weight-loss therapy — how the medications are studied, expected results in trials, and how the research is read.
How GLP3 Weight Loss works as an independent information and research-product resource — our evidence-first approach and our referral model to independent licensed providers.